Hints and tips:
Related Special Reports
...The S&P biotech index is trading about 50 per cent below its peak in February 2021....
...Under 28 U.S.C. section 1408, a company can file bankruptcy in any district where it has its domicile, principal place of business, or principal assets for 180 days prior to bankruptcy....
...Dividends per share had risen just 10 cents since 2011, according to data from S&P Capital IQ....
...London’s unfancied FTSE 100 index, which rose just 3.8 per cent this year against a 24 per cent jump in Wall Street’s S&P 500, was also home to high-street mainstay Marks and Spencer, which took the third...
...The Granolas as a group have climbed 18 per cent over the past 12 months beating the Stoxx 600’s 7.5 per cent rise over the same period....
...The stock bucked the wider pharma sell-off, rising 60 per cent last year. A price to forward earnings multiple of over 50 values the stock more like a tech company than a pharma group....
...The new generation of diet drugs are one of the top trends on calls this year, going well beyond pharma/biotechs....
...German pharma group Boehringer Ingelheim and Copenhagen-based Zealand Pharma said their weight-loss drug had achieved positive results in liver disease trials....
...The S&P 500 closed down almost 1 per cent with roughly nine in every 10 stocks losing ground....
...Just over a decade later I was bemoaning the Götterdämmerung of Big Pharma in the Lombard column....
...A once-popular fund, the SPDR S&P Biotech ETF, has lost 14 per cent of its value this year, falling 60 per cent from its highs....
...But some investors believe selling discipline against a shot is a losing game when big pharma companies are competing to meet the demands of the one in eight people worldwide who are classed as obese....
...The US pharmaceutical company — whose shares are up 130 per cent over the past year and is now a top-10 S&P 500 stock — chose the week of the Oscars to launch an advert called “Big Night”....
...High-grade pharma group Bristol Myers Squibb sold $13bn of debt on Wednesday....
...Novo Nordisk’’s share price closed up 0.7 per cent to DKK1,311 ($190), giving the company a market capitalisation of $428bn. On Friday last week it had briefly dethroned LVMH....
...Biotech business Redx Pharma this week blamed low liquidity on London’s junior market for its decision to delist its shares from Aim and re-register as a private company....
...Coates also narrowly trumps the best-paid executives in the US S&P 500, where Blackstone’s Stephen Schwarzman earned $253mn last year (he separately received about $1bn in dividends) and Alphabet’s Sundar...
...Funds that track US indices will have a much higher exposure to the Mag 7 (currently about 30 per cent for the S&P 500 or as much as 40 per cent for the Nasdaq)....
...In a quieter deal environment, this deal underscores that Big Pharma has the means to make big bets....
...Monday Camillo Pane becomes Alliance Pharma chair, succeeding Jo LeCouilliard China: stock exchanges reopen after Chinese Lunar New Year holiday Germany: Buba Monthly Report Sweden: January consumer...
...It is not a stretch for Sanofi, with a net debt-to-ebitda ratio of 0.6 according to S&P Capital IQ....
...Some investors fear that the uncertainty over Roundup’s financial burden could limit Anderson’s room for manoeuvre with regard to a potential separation of Bayer’s crop science business and its pharma unit...
...It follows Channel 4’s announcement of 200 job cuts, with staff reductions also soon likely at the BBC and ITV. Wuhan in China is emerging as a key testing centre for self-driving cars....
...Oxford’s partnership with the Serum Institute of India, the world’s largest vaccine maker by doses, gives it much bigger production capacity than pharma group GSK has for its RTS,S shot, the first malaria...
...The company subsequently grew by acquiring other companies and counts Platts, part of credit rating company S&P, among its competitors....
International Edition